The devices, kits and methods described herein relate generally to intraocular pressure reduction. More particularly, the devices, kits and methods relate to intraocular implants implantable into Schlemm's canal that can reduce intraocular pressure without substantially interfering with fluid flow across Schlemm's canal.
Glaucoma is a potentially blinding disease that affects over 60 million people worldwide, or about 1-2% of the population. Typically, glaucoma is characterized by elevated intraocular pressure. Increased pressure in the eye can cause damage to the optic nerve which can lead to loss of vision if left untreated. Consistent reduction of intraocular pressure can slow down or stop progressive loss of vision associated with glaucoma. In addition, patients are often diagnosed with pre-glaucoma and ocular hypertension when they exhibit symptoms likely to lead to glaucoma, such as somewhat elevated intraocular pressure, but do not yet show indications of optic nerve damage. Treatments for glaucoma, pre-glaucoma and ocular hypertension primarily seek to reduce intraocular pressure.
Increased intraocular pressure is caused by sub-optimal efflux or drainage of fluid (aqueous humor) from the eye. Aqueous humor or fluid is a clear, colorless fluid that is continuously replenished in the eye. Aqueous humor is produced by the ciliary body, and then flows out primarily through the eye's trabecular meshwork. The trabecular meshwork extends circumferentially around the eye at the anterior chamber angle, or drainage angle, which is formed at the intersection between the peripheral iris or iris root, the anterior sclera or scleral spur and the peripheral cornea. The trabecular meshwork feeds outwardly into Schlemm's canal, a narrow circumferential passageway generally surrounding the exterior border of the trabecular meshwork. Positioned around and radially extending from Schlemm's canal are aqueous veins or collector channels that receive drained fluid. The net drainage or efflux of aqueous humor can be reduced as a result of decreased facility of outflow, decreased outflow through the trabecular meshwork and canal of Schlemm drainage apparatus, increased episcleral venous pressure, or possibly, increased production of aqueous humor. Flow out of the eye can be restricted by blockages or constriction in the trabecular meshwork and/or Schlemm's canal.
Glaucoma, pre-glaucoma and ocular hypertension currently can be treated by reducing intraocular pressure using one or more modalities, including medication, incisional surgery, laser surgery, cryosurgery, and other forms of surgery. In the United States, medications or medical therapy are typically the first lines of therapy. If medical therapy is not sufficiently effective, more invasive surgical treatments may be used. In other countries, such as those with socialized medical systems or with nationalized health care systems, surgery may be the first line of therapy if it is considered a more cost effective treatment.
A standard incisional surgical procedure to reduce intraocular pressure is trabeculectomy, or filtration surgery. This procedure involves creating a new drainage site for aqueous humor. Instead of naturally draining through the trabecular meshwork, a new drainage pathway is created by removing a portion of sclera and trabecular meshwork at the drainage angle. This creates an opening or passage between the anterior chamber and the subconjunctival space that is drained by conjunctival blood vessels and lymphatics. The new opening may be covered with sclera and/or conjuctiva to create a new reservoir called a bleb into which aqueous humor can drain. However, trabeculectomy carries both long and short term risks. These risks include blockage of the surgically-created opening through scarring or other mechanisms, hypotony or abnormally low intraocular pressure, expulsive hemorrhage, hyphema, intraocular infection or endophthalmitis, shallow anterior chamber angle, and others. Alternatives to trabeculectomy are actively being sought.
Bypass stents are also used to bridge a blocked trabecular meshwork. Stents can be inserted between the anterior chamber of the eye and Schlemm's canal, bypassing the trabecular meshwork. However, it is difficult to consistently and reliably implant a bypass stent from the anterior chamber into Schlemm's canal. The implant procedure is challenging and stents can become clogged and lose functionality over time. Others have inserted tubular elongated cylindrical hollow stents longitudinally into Schlemm's canal. Cylindrical hollow stents can be configured to allow circumferential fluid flow around the canal. These too can lose functionality over time as a result of occlusion or scarring.
Schlemm's canal is small, approximately 190-370 microns in cross-sectional diameter, and circular. Therefore, it can be difficult or expensive to design and manufacture hollow tubular stents of appropriate dimensions for use in opening Schlemm's canal. In addition, hollow tubular stents can be prone to failure and collapse or occlusion over time, as has been shown for cardiovascular stents. Hollow tubular stents incorporating thin walls are especially prone to failure. Further, the walls of tubular stents placed lengthwise along Schlemm's canal can have significant surface area contact with the trabecular meshwork and/or the collector channels, which can result in blockage of the meshwork or collector channels, substantially interfering with transmural flow across Schlemm's canal and into the eye's collector channels.
Therefore, easily manufacturable, minimally invasive devices for effective, long-term reduction in intraocular pressure are desirable. In addition, methods and kits incorporating such devices are desirable.
Described here are devices, kits and methods for reducing intraocular pressure. The devices for reducing pressure within the eye comprise a support implantable circumferentially within Schlemm's canal that is configured to maintain the patency of at least a portion of the canal. The support occupies at least a portion of a central core of Schlemm's canal. The support does not substantially interfere with transmural flow across Schlemm's canal, and thereby utilizes the eye's natural drainage pathways. The support can be implanted into Schlemm's canal with minimal trauma to the eye.
The support generally comprises a biocompatible material. At least a portion of the support can be made from a biocompatible polymer, e.g., acrylics, silicones, polymethylmethacrylate, or a hydrogel. In addition, at least part of the support can be made from a biocompatible metal such as gold. In some variations, at least a portion of the support is made from a shape memory material. Suitable shape memory materials include shape memory polymers or shape memory alloys, such as nickel titanium alloys. If a shape memory material is used, the support can have a compressed state prior to and during implantation into Schlemm's canal, and an expanded state following implantation to open the canal.
In some variations, the support is at least partially made from a biocompatible, biodegradable polymer. The biodegradable polymer can be collagen, a collagen derivative, a poly(lactide); a poly(glycolide); a poly(lactide-co-glycolide); a poly(lactic acid); a poly(glycolic acid); a poly(lactic acid-co-glycolic acid); a poly(lactide)/poly(ethylene glycol) copolymer; a poly(glycolide)/poly(ethylene glycol) copolymer; a poly(lactide-co-glycolide)/poly(ethylene glycol) copolymer; a poly(lactic acid)/poly(ethylene glycol) copolymer; a poly(glycolic acid)/poly(ethylene glycol) copolymer; a poly(lactic acid-co-glycolic acid)/poly(ethylene glycol) copolymer; a poly(caprolactone); a poly(caprolactone)/poly(ethylene glycol) copolymer; a polyorthoester; a poly(phosphazene); a poly(hydroxybutyrate) or a copolymer including a poly(hydroxybutyrate); a poly(lactide-co-caprolactone); a polycarbonate; a poly(esteramide); a polyanhydride; a poly(dioxanone); a poly(alkylene alkylate); a copolymer of polyethylene glycol and a polyorthoester; a biodegradable polyurethane; a poly(amino acid); a polyetherester; a polyacetal; a polycyanoacrylate; a poly(oxyethylene)/poly(oxypropylene) copolymer; and blends and copolymers thereof.
The support can comprise an active agent. For example, a support can be coated or impregnated with an active agent. Alternatively, an active agent can be dispersed within the support, e.g., by filling a cavity within the support. The active agent can include a prostaglandin, a prostaglandin analog, a beta blocker, an alpha-2 agonist, a calcium channel blocker, a carbonic anhydrase inhibitor, a growth factor, an anti-metabolite, a chemotherapeutic agent, a steroid, an antagonist of a growth factor, or combinations thereof. The release of the active agent can be controlled using a time release system, e.g., by embedding or encapsulating the active agent with a time release composition.
In some variations, the support will be solid. In other variations, at least a portion of the support will be hollow or porous. The surface of the support may be smooth, rough, spiked, or fluted. In still other variations, at least part of the support will be made from mesh. The support can include at least one fenestration and one or more rod-like members.
In some variations, the support comprises at least two adjacent beads. Adjacent beads can have the same or different sizes and shapes, and can be made from the same or different materials. The bead shapes can be spherical, spheroid, ovoid, cylindrical, cuboid, cubical, conical, discoid, helical, or segments thereof. In some variations, there is a connector linking at least two adjacent beads together. If there is a connector, it can be rigid or flexible. If there is more than one connector, e.g., two connectors inserted between three beads, the connectors may be of the same or different lengths. The connectors can include the same or different material as the beads they connect. A connector can also function as a spacer configured to provide space between adjacent beads. In some variations, the support comprises at least two discs separated by, and connected with, a connector. The discs may include fenestrations. The connector may also comprise a guide wire over which a fenestrated bead can be threaded into the canal of Schlemm.
The support can extend approximately all the way around Schlemm's canal, if the support has a circumference approximately equal to the circumference of Schlemm's canal. Alternatively, the support can extend only about half way around the circumference of Schlemm's canal, or about a quarter way around the canal. In some variations, the support will extend less than a quarter circumference of Schlemm's canal. The support can be configured to contact the inner surface of the wall of Schlemm's canal at two, three or more points. In some variations, the support can be attached to tissue. The support may comprise a stiff arcuate member having a radius of curvature smaller or larger than that of Schlemm's canal.
In some variations, the support can be altered using electromagnetic radiation. For example, a laser having a wavelength absorbable by at least one localized portion of the support can be used to alter the support. In other variations, electromagnetic radiation can be used to release an active agent from the support. In still other variations, the support can be visually enhanced using fluorescence or phosphorescence emission. For example, the support can comprise a chromophore that fluoresces or phosphoresces upon excitation with a light source. In some variations, the emitted fluorescence or phosphorescence is in the wavelength range of about 300 nm to about 800 nm. In some variations, the support can comprise a chromophore that enhances postoperative monitoring of the support.
Kits for reducing intraocular pressure are also provided. The kits contain a support that can be implanted circumferentially within Schlemm's canal. The support is configured to maintain the patency of at least part of Schlemm's canal. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across the canal. The kits also contain an introducer for implanting the support within the canal. In some variations, the kits include a positioning device for adjusting the support within the canal. In other variations, kits include instructions. In still other variations, the kits include an active agent. Some kits contain at least two supports. If more than one support is included, the kits can include at least two introducers for delivering the supports. Multiple supports within the same kit can have the same or different shape, size, or composition. Multiple supports within the same kit can be connected together or remain separate. In some variations, kits include a fixation device for attaching a support to tissue. In other variations, kits may include a system for visually enhancing the appearance of the support.
Methods for reducing intraocular pressure are also described. The methods include inserting a support circumferentially within Schlemm's canal. The support is configured to maintain the patency of at least part of the canal. The support occupies at least a portion of a central core of Schlemm's canal, and does not substantially interfere with transmural flow across the canal. In some variations, the methods also include dilating Schlemm's canal prior to insertion of the support. In still other variations, the methods comprise anchoring the support to tissue. The methods can include implanting at least two supports. If more than one support is implanted within a single eye, the multiple supports can be positioned circumferentially adjacent to each other or circumferentially opposed (i.e., positioned about 180° apart) to each other within Schlemm's canal. Multiple supports within one eye can be connected or remain separate. In some variations of the methods, the support is illuminated with a light source to visually enhance the position of the support. In other variations of the methods, the support can be altered using electromagnetic radiation. For example, a laser absorbed by at least one localized portion of the support can be used to alter the support. The alteration can comprise the creation or enlargement of an aperture in the support. If electromagnetic radiation is used to alter a support, the alteration can occur before implantation or after implantation.
Described here are devices, kits and methods to reduce intraocular pressure by maintaining or restoring Schlemm's canal so that at least a portion of the canal is patent or unobstructed. The devices, kits and methods operate to keep Schlemm's canal from collapsing while not substantially interfering with the eye's natural drainage mechanism for aqueous humor, in which transmural fluid flow across Schlemm's canal occurs. The devices are implantable in Schlemm's canal with minimal trauma to the eye.
With reference to the figures,
Different fluid flow paths in and across Schlemm's canal are illustrated in
Devices
Devices to reduce intraocular pressure comprising a support that can be implanted circumferentially in Schlemm's canal to maintain the patency of at least a portion of the canal are described here. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across the canal. By “maintain the patency” of at least a portion the canal, it is meant that the support operates to keep the canal at least partially unobstructed to transmural flow, such that fluid can 1) exit through the trabecular meshwork; 2) traverse the canal; and 3) drain via the collector channels. To maintain the patency of the canal, it is not necessary that the support leave the canal unobstructed in regard to circumferential flow. By “does not substantially interfere” with transmural flow, it is meant that the support does not significantly block either fluid outflow from the trabecular meshwork or fluid outflow to the collector channels. In many variations, the support allows between about 0.1 and about 5 microliters per minute aqueous outflux from the eye through the trabecular meshwork and collector channels. The “central core of Schlemm's canal” refers to the region around the cross-sectional center of the canal in the interior space of the canal lumen, i.e., not on the periphery of the canal. Therefore, a device that occupies at least a portion of a central core of Schlemm's canal can traverse at least a portion of the canal's lumen.
Therefore, devices described here need not comprise an open-ended tubular support placed longitudinally along Schlemm's canal, i.e., the devices and supports can be non-tubular. A longitudinal, open-ended tubular support can enable longitudinal flow along the canal. However, even if fluid can flow longitudinally (i.e., circumferentially) along Schlemm's canal, the eye may not be effectively drained unless the fluid eventually traverses the canal. That is, transmural fluid flow across two boundaries must occur: 1) fluid must flow from the trabecular meshwork through a canal inner wall coincident with an outer peripheral boundary of the trabecular meshwork to reach the canal lumen; and 2) fluid must flow from the canal lumen through apertures in the canal outer peripheral wall to reach the connector channels. The collector channels are then able to further disperse the fluid and complete the natural draining process. A tubular support inserted longitudinally into the canal can have significant surface area overlap with surfaces of the canal such that transmural flow across the canal may be significantly impeded. A longitudinal tubular support placed in Schlemm's canal may block flow into the canal from the trabecular meshwork and block flow out of the canal into the collector channels.
Devices described herein for treating elevated intraocular pressure include a support that is implanted within Schlemm's canal. In many instances, the device will reduce the intraocular pressure by 1-40 mm Hg, for example by at least 2 mm Hg. In other instances, the device will reduce intraocular pressure by at least 4 mm Hg, or at least 6 mm Hg, or at least 10 or 20 mm Hg. In still other instances, the device will operate to bring the intraocular pressure into the range of about 8 to about 22 mm Hg. The support can be configured in a variety of ways to at least partially prop open Schlemm's canal thereby maintaining its patency without substantially interfering with or impeding transmural fluid flow across Schlemm's canal. In some variations, the support may interfere with or block longitudinal flow along or around the canal. In many instances, the support will be contained entirely within Schlemm's canal. In some variations the support will be implanted within the canal, but may extend partially beyond Schlemm's canal, e.g., into the trabecular meshwork.
In some variations, a support to maintain at least partial patency for Schlemm's canal to enable fluid flow between an inner wall of the canal and an outer wall of the canal can comprise elements or structures such as bead-like elements or beads, which can be connected together, e.g., as a string of beads. Individual elements or beads or a connected group of elements or beads can be inserted directly into Schlemm's canal. A more detailed description of supports incorporating elements or beads is provided below.
Elements or beads used in a support may be hollow and closed structures, open structures, solid structures, porous structures, or any combination thereof, and may be of any suitable shape.
As illustrated in the variations shown in
Junctions 102 between beads as shown in
As shown in
Supports of the devices described here need not contain beads. For example, a support can be a unitary structure of fixed or variable length. Supports can be solid, hollow, or porous, or any combination thereof. For example, a support can be partially solid and partially hollow. Examples of support configurations are shown in side view and front view in
A common characteristic of the support configurations described here is that they need not have continuous or extensive contact with a wall of Schlemm's canal. Indeed, many of the described devices and structures have minimal tangential, periodic, or sporadic contact with the wall. The surface of the support can be rough, smooth, spiked or fluted. As the example shown in
Expanded cross-sectional views of a support 152 implanted circumferentially in Schlemm's canal are provided
Supports can have variable lengths and thicknesses. For example, the length of supports using beads can be tuned by varying the number, type, or spacing of beads, or any combination thereof. The thickness of a support can be increased by adding one or more beads having larger dimensions. Unitary supports can also be built with varying lengths, or with adjustable (e.g., trimmable) dimensions. For example, for a support made of shapeable metal having a sinusoidal or zig-zag configuration as shown
A support can be configured such that it will open the canal beyond a maximum cross-sectional dimension of the support itself. For example, as illustrated in
The supports described here occupy at least a portion of a central core of Schlemm's canal. The central core of Schlemm's canal is the region around the cross-sectional center of the canal in the interior space of the canal lumen. A support that occupies at least a portion of the central core of the canal can traverse at least a portion of the canal lumen. For example, some variations of supports can traverse the cross-sectional center of the canal at at least one point. Referring to
A support can made of a variety of different materials. In general, the support should comprise a biocompatible material, such as a biocompatible polymer, ceramic or ceramic composite, glass or glass composite, metal, or combinations of these materials. Examples of biocompatible metals include stainless steel, gold, silver, titanium, tantalum, platinum and alloys thereof, cobalt and chromium alloys, and titanium nickel alloys such as Nitinol. Examples of biocompatible polymers include high density polyethylene, polyurethane, polycarbonate, polypropylene, polymethylmethacrylate, polybutylmethacryate, polyesters, polytetrafluoroethylene, silicone, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl chloride, ethyl vinyl acetate, collagen, collagen derivatives, flexible fused silica, polyolefins, NYLON® polymer, polyimide, polyacrylamide, fluorinated elastomers, and copolymers and blends thereof. In addition, biocompatible hydrogels can be used in supports and devices described herein. As discussed in more detail below, biocompatible polymers may be biodegradable. A support can be made of a single material or a combination of materials. In some variations, a support made from a first material is coated with a second material, e.g., to enhance or improve its biocompatibility.
In some examples, the biocompatible polymer in a support will include a biodegradable polymer. Examples of suitable biodegradable polymers include collagen, a collagen derivative, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a poly(lactide)/poly(ethylene glycol) copolymer, a poly(glycolide)/poly(ethylene glycol) copolymer, a poly(lactide-co-glycolide)/polyethylene glycol) copolymer, a poly(lactic acid)/poly(ethylene glycol) copolymer, a poly(glycolic acid)/poly(ethylene glycol) copolymer, a poly(lactic acid-co-glycolic acid)/poly(ethylene glycol) copolymer, a poly(caprolactone), a poly(caprolactone)poly(ethylene glycol) copolymer, a polyorthoester, a poly(phosphazene), a poly(hydroxybutyrate) or a copolymer including a poly(hdroxybutyrate), a poly(lactide-co-caprolactone), a polycarbonate, a poly(esteramide), a polyanydride, a poly(dioxanone), a poly(alykylene alkylate), a copolymer of polyethylene glycol and a polyorthoester, a biodegradable polyurethane, a poly(amino acid), a polyetherester, a polyacetal, a polycyanoacrylate, a poly(oxyethylene)/poly(oxypropylene) copolymer, and blends and copolymers thereof.
At least a portion of the support can be made from a shape memory material. For example, shape memory alloys, e.g. a nickel-titanium alloy can be used. In addition, shape memory polymers, e.g., polymers made from copolymerizing monomers oligo(e-caprolactone) dimethacrylate and n-butyl acrylate or polymers based on styrene acrylate, cyanate ester and epoxies, can be used. If a shape memory material is used in the support, the support can have a compressed state prior to and during implantation, and an expanded state following implantation. The use of a compressed state support comprising a shape memory material can allow for a smaller incision and facilitate insertion into a narrowed or compressed Schlemm's canal. Once implanted, the support can be expanding using any suitable method, e.g., thermally activated by body heat or an alternate heat source, to adopt an expanded state, thereby opening the canal.
The support can include an active agent, such as a pharmaceutical. Active agents can include prostaglandins, prostaglandin analogs, beta blockers, alpha-2 agonists, calcium channel blockers, carbonic anhydrase inhibitors, growth factors, such as tissue growth factors and vascular endothelial growth factors, anti-metabolites, chemotherapeutic agents such as mitomycin-C,5-fluorouracil, steroids, antagonists of growth factors such as antagonists of vascular endothelial growth factors, or combinations thereof. The active agent can be provided as a coating on at least a portion of a support. The active agent can be delivered throughout the eye by dissolution or other dispersal mechanisms. Alternatively, at least a portion of the support can be impregnated with the active agent. In other embodiments, the active agent can be dispersed within at least a portion of the support. For example, a cavity in the support can be filled with the active agent.
The delivery of the active agent can be controlled by time-release. For example, the portion of the support containing the active agent can include a time release coating or time release formulation designed to gradually dissipate the active agent over a certain period of time. Biodegradable coatings and formulations for time-release of active agents are known in the art. In some variations, the support can comprise multiple layers, where the layers each comprise an active agent. For example, support layers can be used to release a series of different agents, or a series of doses of the same agent. Such layers can be part of a coating applied to a support, or part of a support body. In addition, the support can comprise biodegradable layers containing no active agent that can be applied or interspersed between other layers to further control delivery of active agents to the eye.
In some variations, it will be desirable to change or alter the support using electromagnetic radiation. For example, at least a portion of a support can be fenestrated, perforated, bent, shaped or formed using a laser to enhance intraocular pressure reduction. As illustrated in
In some variations, the visual appearance of the support can be enhanced under certain conditions to facilitate placement or to monitor the position or condition of the support. Visual enhancement can be achieved by incorporating into or onto the support chromophores that fluoresce or phosphoresce upon excitation with a light source. Chromophores can also assist a clinician in verifying the position of the support postoperatively using a gonioscope, for example. Light sources can include lasers, lamps, and light emitting diodes. In some instances, transmission or absorption filters may be used to select the wavelength of the excitation source or to detect or view emission. Emission from a support capable of visual enhancement may be in the wavelength range of about 300 nm to about 800 nm. The chromophores can be an integral component of the material making up the support, doped into support material, or coated or sprayed onto the support. Visually-enhancing chromophores can be applied on a temporary basis, or on a permanent basis. An example of a suitable chromophore is fluorescein, which can be excited with any laser or lamp emitting at about 400 to about 500 nm. In addition, phosphorus-based chemiluminescent or photoluminscent pigments can be used, which can be selected to absorb at various wavelengths across the visible spectrum.
In some variations, the support may be capable of being attached to tissue. For example, the support may include a hook, loop, clip, extension, or the like that may be easily attached to tissue. The support may also be attached to tissue using sutures or adhesives. The support may be attached to tissue using more than one attachment method, e.g., suturing may be used in combination with a loop, or an adhesive may be used in combination with a hook. In other variations, the support may be allowed to self-position in Schlemm's canal. In still other variations, the support may be mobile within Schlemm's canal.
Kits
Kits for reducing intraocular pressure are provided, where the kits contain at least one support that can be implanted circumferentially within Schlemm's canal configured to maintain the patency of at least a portion of Schlemm's canal. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across the canal. The kits also provide an introducer or delivery device for implanting the support in the canal. The support and introducer are provided in packaged combination in the kits. The kits can also include instructions for use, e.g., for implanting and inspecting the support.
The introducer can be inserted into the eye and is capable of implanting the support at the desired implantation position within Schlemm's canal. For example, an introducer may include a tubular cannula through which the support may be passed. In addition to a cannula, the introducer may include a tubular or solid pusher rod that can be used to push or advance the support into and/or around Schlemm's canal. Alternatively, a pusher rod or plunger can be used without a cannula to introduce a support into the canal. A support can be installed into the lumen of a cannula prior to insertion, the distal end of the cannula positioned at or near the desired support location, and the pusher rod operated from the proximal end to push the support distally out of the distal end of the cannula and into the canal. The cannula and/or the pusher rod may be flexible and small enough in diameter to extend at least partially around the canal. In some variations, a proximal end of a suture can be introduced into the canal via a cannula and the suture extended circumferentially around the canal. A distal portion of the suture can be connected to the support and force applied to the proximal end of the suture to pull the support into the canal. The support can then be positioned within the canal by pulling the suture in a distal or proximal direction. The suture can be used to anchor the support within the canal. In other variations, the support can be directly introduced into the canal using surgical forceps, or the like.
In some variations, a positioning device may be used with the introducer to position or adjust the support within the canal. A positioning device can include a rod, grippers, a clamp, a hook, or the like. In other variations, a device or system capable of dilating the canal to facilitate insertion of a support may be included in the kits, e.g., a syringe or other device capable of injecting fluid into the canal.
In some variations, the kits contain at least two supports. Multiple supports can be implanted within one eye or within multiple eyes. If the kits contain multiple supports, the kits may also contain multiple introducers. Alternatively, the same introducer may be used for implantation of multiple supports, especially if the multiple supports are being delivered to a single eye. If multiple supports are to be delivered with the same introducer, then the multiple supports can be preloaded into the introducer for sterility. If more than one support is included in a kit, the supports may be of different shapes, sizes, lengths, or materials. If the kits contain more than one support to be implanted into a single eye, the supports can be connected together.
The kits can comprise an active agent, such as a pharmaceutical agent. The active agent may be included as an integral part of the support, or may be supplied in kits for application to the support or to the eye during or after implantation. Examples of active agents that may be supplied as part of the kits include prostaglandins, prostaglandin analogs, beta blockers, alpha-2 agonists, calcium channel blockers, carbonic anhydrase inhibitors, growth factors, such as tissue growth factors or vascular endothelial growth factors, anti-metabolites, chemotherapeutic agents such as mitomycin-C,5-fluorouracil, steroids, antagonists of growth factors, such as antagonists of vascular endothelial growth factor, and combinations thereof.
The kits may contain a fixation device for attaching a support to tissue. Such a fixation device can include sutures, hooks, barbs, clips, adhesives, and combinations thereof. In addition, the kits may include a system for visually enhancing the support to facilitate viewing, positioning, and monitoring of a support. A system for visually enhancing the support can include a light source, a transmission or absorption filter, a mirror, a composition comprising a chromophore capable of fluorescing or phosphorescing that can be applied to the support, or any combination thereof. Chromophores can assist a clinician in verifying the position of the support postoperatively using a gonioscope, for example. The light source is capable of exciting a chromophore contained within or on the support such that the chromophore emits fluorescence or phosphorescence. The emission is preferably within the wavelength range of about 300 nm to about 800 nm. A suitable light source for such a system can comprise a laser, a light emitting diode, or a lamp. In some instances, transmission or absorption filters may be used to further select the wavelength range of the excitation source or view or detect emission from chromophores. One or more mirrors may be used to direct a light source or emitted light, or to view the support.
Methods
Methods for reducing intraocular pressure are also provided. In general, the methods comprise inserting a support circumferentially within Schlemm's canal, such that the support maintains the patency of at least a portion of the canal. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across Schlemm's canal.
The methods can comprise inserting a support circumferentially into Schlemm's canal using an introducer and/or a positioning device. The introducer can include a cannula and a tubular or hollow pusher rod. The support can be installed in the lumen of the cannula at its distal end and the pusher rod can be inserted into the lumen of the cannula at its proximal end and extended distally to push the support into position in the canal. In some instances, the cannula and/or the pusher rod may be flexible and small enough in diameter to at least partially extend circumferentially around the canal. In some variations of the methods, a positioning device can be used in addition to an introducer. The positioning device can comprise a second rod, a gripper, a hook, a clamp, or the like. In some variations, the methods include illuminating a support with a light source to causes the support to fluoresce or phosphoresce, thus aiding the visual appearance of the support. The illuminating of the support can occur during or after implantation to inspect the support, e.g., to monitor its position, condition, or performance.
In some instances, the methods will also comprise dilating Schlemm's canal prior to insertion of the support. Dilation of the canal can be accomplished by injecting fluid into the canal. For example, a high viscosity fluid such as sodium hyaluronate, or other dilating fluids known in the art, can be used to dilate the canal.
The methods may include implanting more than one support into an eye. In some variations, the methods will include implantation of two or more supports circumferentially adjacent to each other within the canal, and in other variations, the methods will include implantation of supports circumferentially opposed to each other within the canal, e.g., two supports centered about 180° apart around the circumference of Schlemm's canal. Some variations of the methods can comprise connecting together multiple supports in a single eye.
In some variations, the methods can include anchoring the support to tissue surrounding Schlemm's canal. Anchoring the support to tissue can be accomplished in a variety of ways, e.g., by suturing, application of adhesives, installation of hooks, clips, or the like, or combinations thereof. In other variations, the methods can comprise selecting the size of the support such that the support fits securely into the canal by a friction fit. Examples of arcuate supports that can be implanted with a friction fit are illustrated in
The methods described here can also include altering the support using electromagnetic radiation. For example, a support can include regions capable of preferentially absorbing a certain wavelength range. When electromagnetic radiation of the appropriate wavelength range with sufficient energy is incident upon the support, material in the preferentially absorbing regions will melt or ablate, resulting in perforations or indentations in the support at those regions. For example, a pulsed titanium sapphire laser emitting at about 750 nm to about 800 nm incident on gold can cause the gold to melt or ablate. The alteration of the support using electromagnetic radiation can occur before or after implantation of a support. For example, fenestrations can be created or enlarged in a support after the support has remained in an eye for a period of time to enhance drainage.
While the inventive devices, kits and methods have been described in some detail by way of illustration, such illustration is for purposes of clarity of understanding only. It will be readily apparent to those of ordinary skill in the art in light of the teachings herein that certain changes and modifications may be made thereto without departing from the spirit and scope of the appended claims. For example, it is envisioned that the devices, kits and methods can be applied to nonhuman eyes to reduce intraocular pressure, e.g., in dogs, cats, primates, or horses.
This application is a continuation of U.S. patent application Ser. No. 13/025,112, filed Feb. 10, 2011, now issued as U.S. Pat. No. 9,370,443, which is a divisional of U.S. patent application Ser. No. 11/475,523, filed Jun. 26, 2006, now issued as U.S. Pat. No. 7,909,789, each of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3159161 | Ness | Dec 1964 | A |
4068664 | Sharp et al. | Jan 1978 | A |
4457757 | Molteno | Jul 1984 | A |
4501274 | Skjaerpe | Feb 1985 | A |
4553545 | Maass et al. | Nov 1985 | A |
4719825 | LaHaye et al. | Jan 1988 | A |
4936825 | Ungerleider | Jun 1990 | A |
4957505 | McDonald | Sep 1990 | A |
5092837 | Ritch et al. | Mar 1992 | A |
5180362 | Worst | Jan 1993 | A |
5284476 | Koch | Feb 1994 | A |
5358473 | Mitchell | Oct 1994 | A |
5360399 | Stegmann | Nov 1994 | A |
5368572 | Shirota | Nov 1994 | A |
5486165 | Stegmann | Jan 1996 | A |
5540657 | Kurjan et al. | Jul 1996 | A |
5558634 | Mitchell | Sep 1996 | A |
5569197 | Helmus et al. | Oct 1996 | A |
5626558 | Suson | May 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5792099 | DeCamp et al. | Aug 1998 | A |
5792103 | Schwartz et al. | Aug 1998 | A |
5868697 | Richter et al. | Feb 1999 | A |
6036678 | Giungo | Mar 2000 | A |
6050970 | Baerveldt | Apr 2000 | A |
6050999 | Paraschac et al. | Apr 2000 | A |
6299603 | Hecker et al. | Oct 2001 | B1 |
6309375 | Glines et al. | Oct 2001 | B1 |
6375642 | Grieshaber et al. | Apr 2002 | B1 |
6491670 | Toth et al. | Dec 2002 | B1 |
6494857 | Neuhann | Dec 2002 | B1 |
6508779 | Suson | Jan 2003 | B1 |
6524275 | Lynch et al. | Feb 2003 | B1 |
6533768 | Hill | Mar 2003 | B1 |
6616996 | Keith et al. | Sep 2003 | B1 |
6626858 | Lynch et al. | Sep 2003 | B2 |
6666841 | Gharib et al. | Dec 2003 | B2 |
6726676 | Stegmann et al. | Apr 2004 | B2 |
6730056 | Ghaem et al. | May 2004 | B1 |
6736791 | Tu et al. | May 2004 | B1 |
6780164 | Bergheim et al. | Aug 2004 | B2 |
6783544 | Lynch et al. | Aug 2004 | B2 |
6840952 | Saker et al. | Jan 2005 | B2 |
6843792 | Nishtala et al. | Jan 2005 | B2 |
6893415 | Madsen et al. | May 2005 | B2 |
6955656 | Bergheim et al. | Oct 2005 | B2 |
6962573 | Wilcox | Nov 2005 | B1 |
7094225 | Tu et al. | Aug 2006 | B2 |
7135009 | Tu et al. | Nov 2006 | B2 |
7186232 | Smedley et al. | Mar 2007 | B1 |
7207980 | Christian et al. | Apr 2007 | B2 |
7273475 | Tu et al. | Sep 2007 | B2 |
7297130 | Bergheim et al. | Nov 2007 | B2 |
7331984 | Tu et al. | Feb 2008 | B2 |
7488303 | Haffner et al. | Feb 2009 | B1 |
7713228 | Robin | May 2010 | B2 |
7740604 | Schieber et al. | Jun 2010 | B2 |
7806847 | Wilcox | Oct 2010 | B2 |
7850637 | Lynch et al. | Dec 2010 | B2 |
7867205 | Bergheim et al. | Jan 2011 | B2 |
7909789 | Badawi et al. | Mar 2011 | B2 |
7951155 | Smedley et al. | May 2011 | B2 |
7967772 | McKenzie et al. | Jun 2011 | B2 |
8034105 | Stegmann et al. | Oct 2011 | B2 |
8075511 | Tu et al. | Dec 2011 | B2 |
8109896 | Nissan et al. | Feb 2012 | B2 |
8123729 | Yamamoto et al. | Feb 2012 | B2 |
8133208 | Hetherington | Mar 2012 | B2 |
8152752 | Lynch et al. | Apr 2012 | B2 |
8172899 | Silvestrini et al. | May 2012 | B2 |
8267882 | Euteneuer et al. | Sep 2012 | B2 |
8273050 | Bergheim et al. | Sep 2012 | B2 |
8282592 | Schieber et al. | Oct 2012 | B2 |
8287482 | Badawi et al. | Oct 2012 | B2 |
8333742 | Bergheim et al. | Dec 2012 | B2 |
8337509 | Schieber et al. | Dec 2012 | B2 |
8348924 | Christian et al. | Jan 2013 | B2 |
8366653 | Shareef et al. | Feb 2013 | B2 |
8372026 | Schieber et al. | Feb 2013 | B2 |
8388568 | Lynch et al. | Mar 2013 | B2 |
8403920 | Lind et al. | Mar 2013 | B2 |
8414518 | Schieber et al. | Apr 2013 | B2 |
8425449 | Wardle et al. | Apr 2013 | B2 |
8425450 | Wilcox | Apr 2013 | B2 |
8439972 | Badawi et al. | May 2013 | B2 |
8444589 | Silvestrini | May 2013 | B2 |
8491549 | Conston et al. | Jul 2013 | B2 |
8512321 | Baerveldt et al. | Aug 2013 | B2 |
8512404 | Frion et al. | Aug 2013 | B2 |
8529622 | Badawi et al. | Sep 2013 | B2 |
8540659 | Berlin | Sep 2013 | B2 |
8540681 | Hetherington | Sep 2013 | B2 |
8545431 | Rickard | Oct 2013 | B2 |
8568391 | Kearns et al. | Oct 2013 | B2 |
8617094 | Smedley et al. | Dec 2013 | B2 |
8657776 | Wardle et al. | Feb 2014 | B2 |
8663150 | Wardle et al. | Mar 2014 | B2 |
8715266 | Bos | May 2014 | B2 |
8734377 | Schieber et al. | May 2014 | B2 |
8747299 | Grieshaber | Jun 2014 | B2 |
8771217 | Lynch et al. | Jul 2014 | B2 |
8801648 | Bergheim et al. | Aug 2014 | B2 |
8808222 | Schieber et al. | Aug 2014 | B2 |
8827990 | Van Valen et al. | Sep 2014 | B2 |
8852137 | Horvath et al. | Oct 2014 | B2 |
8876898 | Badawi et al. | Nov 2014 | B2 |
8888734 | Nissan et al. | Nov 2014 | B2 |
8894603 | Badawi et al. | Nov 2014 | B2 |
8926546 | Wilcox | Jan 2015 | B2 |
8961447 | Schieber et al. | Feb 2015 | B2 |
9039650 | Schieber et al. | May 2015 | B2 |
9044301 | Pinchuk et al. | Jun 2015 | B1 |
9050169 | Schieber et al. | Jun 2015 | B2 |
9066750 | Wardle et al. | Jun 2015 | B2 |
9066783 | Euteneuer et al. | Jun 2015 | B2 |
9095412 | Badawi et al. | Aug 2015 | B2 |
9107729 | Sorensen et al. | Aug 2015 | B2 |
9125723 | Horvath et al. | Sep 2015 | B2 |
9155655 | Schieber et al. | Oct 2015 | B2 |
9192516 | Horvath et al. | Nov 2015 | B2 |
9211213 | Wardle et al. | Dec 2015 | B2 |
9216109 | Badawi et al. | Dec 2015 | B2 |
9220632 | Smedley et al. | Dec 2015 | B2 |
9226850 | Baerveldt et al. | Jan 2016 | B2 |
9226852 | Schieber et al. | Jan 2016 | B2 |
9301875 | Tu et al. | Apr 2016 | B2 |
9326891 | Horvath et al. | May 2016 | B2 |
9339514 | Bos et al. | May 2016 | B2 |
9351874 | Schieber et al. | May 2016 | B2 |
9358155 | Sorensen et al. | Jun 2016 | B2 |
9358156 | Wardle et al. | Jun 2016 | B2 |
9370443 | Badawi | Jun 2016 | B2 |
9381111 | Hickingbotham et al. | Jul 2016 | B2 |
9402767 | Schieber et al. | Aug 2016 | B2 |
9486361 | Badawi | Nov 2016 | B2 |
9492319 | Grieshaber et al. | Nov 2016 | B2 |
9492320 | Lynch et al. | Nov 2016 | B2 |
9510973 | Wardle | Dec 2016 | B2 |
9855167 | Badawi et al. | Jan 2018 | B2 |
9895258 | Badawi et al. | Feb 2018 | B2 |
20010014788 | Morris | Aug 2001 | A1 |
20020013546 | Grieshaber et al. | Jan 2002 | A1 |
20020013572 | Berlin | Jan 2002 | A1 |
20020055753 | Silvestrini | May 2002 | A1 |
20020072673 | Yamamoto et al. | Jun 2002 | A1 |
20020133168 | Smedley et al. | Sep 2002 | A1 |
20020143284 | Tu et al. | Oct 2002 | A1 |
20030060447 | Karakelle et al. | Mar 2003 | A1 |
20030060873 | Gertner et al. | Mar 2003 | A1 |
20030120200 | Bergheim et al. | Jun 2003 | A1 |
20030181848 | Bergheim et al. | Sep 2003 | A1 |
20030229303 | Haffner et al. | Dec 2003 | A1 |
20030236483 | Ren | Dec 2003 | A1 |
20030236484 | Lynch et al. | Dec 2003 | A1 |
20040044310 | Suzuki | Mar 2004 | A1 |
20040193095 | Shadduck | Sep 2004 | A1 |
20040193262 | Shadduck | Sep 2004 | A1 |
20040210181 | Vass et al. | Oct 2004 | A1 |
20040254519 | Tu et al. | Dec 2004 | A1 |
20040254520 | Porteous et al. | Dec 2004 | A1 |
20040254521 | Simon | Dec 2004 | A1 |
20040260228 | Lynch et al. | Dec 2004 | A1 |
20050055082 | Ben Muvhar et al. | Mar 2005 | A1 |
20050101967 | Weber et al. | May 2005 | A1 |
20050171507 | Christian | Aug 2005 | A1 |
20050192527 | Gharib et al. | Sep 2005 | A1 |
20050209549 | Bergheim et al. | Sep 2005 | A1 |
20050250788 | Tu et al. | Nov 2005 | A1 |
20050266047 | Tu et al. | Dec 2005 | A1 |
20050267555 | Marnfeldt et al. | Dec 2005 | A1 |
20050277864 | Haffner et al. | Dec 2005 | A1 |
20050288619 | Gharib et al. | Dec 2005 | A1 |
20060032507 | Tu | Feb 2006 | A1 |
20060036207 | Koonmen et al. | Feb 2006 | A1 |
20060069340 | Simon | Mar 2006 | A1 |
20060074375 | Bergheim et al. | Apr 2006 | A1 |
20060084907 | Bergheim et al. | Apr 2006 | A1 |
20060149194 | Conston | Jul 2006 | A1 |
20060155300 | Stamper et al. | Jul 2006 | A1 |
20060173077 | Cagle | Aug 2006 | A1 |
20060173397 | Tu et al. | Aug 2006 | A1 |
20060173446 | Dacquay et al. | Aug 2006 | A1 |
20060195055 | Bergheim et al. | Aug 2006 | A1 |
20060195056 | Bergheim et al. | Aug 2006 | A1 |
20060195187 | Stegmann et al. | Aug 2006 | A1 |
20060200113 | Haffner et al. | Sep 2006 | A1 |
20060217741 | Ghannoum | Sep 2006 | A1 |
20060241580 | Mittelstein et al. | Oct 2006 | A1 |
20070073275 | Conston et al. | Mar 2007 | A1 |
20070106236 | Coroneo | May 2007 | A1 |
20070191863 | De Juan, Jr. et al. | Aug 2007 | A1 |
20070260173 | Boukhny et al. | Nov 2007 | A1 |
20070276420 | Sorensen et al. | Nov 2007 | A1 |
20080004596 | Yun et al. | Jan 2008 | A1 |
20080058704 | Hee et al. | Mar 2008 | A1 |
20080058760 | Agerup | Mar 2008 | A1 |
20080082078 | Berlin | Apr 2008 | A1 |
20080300574 | Belson et al. | Dec 2008 | A1 |
20090036819 | Tu et al. | Feb 2009 | A1 |
20090043321 | Conston et al. | Feb 2009 | A1 |
20090082862 | Schieber et al. | Mar 2009 | A1 |
20090132040 | Frion et al. | May 2009 | A1 |
20090227934 | Euteneuer et al. | Sep 2009 | A1 |
20090247955 | Yamamoto et al. | Oct 2009 | A1 |
20090287143 | Line | Nov 2009 | A1 |
20090287233 | Huculak | Nov 2009 | A1 |
20100019177 | Luckevich | Jan 2010 | A1 |
20100087774 | Haffner et al. | Apr 2010 | A1 |
20100121248 | Yu et al. | May 2010 | A1 |
20100173866 | Hee et al. | Jul 2010 | A1 |
20100179652 | Yamamoto et al. | Jul 2010 | A1 |
20100222802 | Gillespie | Sep 2010 | A1 |
20100241046 | Pinchuk et al. | Sep 2010 | A1 |
20100262174 | Sretavan et al. | Oct 2010 | A1 |
20110009874 | Wardle et al. | Jan 2011 | A1 |
20110009958 | Wardle et al. | Jan 2011 | A1 |
20110098809 | Wardle et al. | Apr 2011 | A1 |
20110224597 | Stegmann et al. | Sep 2011 | A1 |
20110238009 | Meron et al. | Sep 2011 | A1 |
20110238075 | Clauson et al. | Sep 2011 | A1 |
20110306915 | De Juan, Jr. et al. | Dec 2011 | A1 |
20120010702 | Stegmann et al. | Jan 2012 | A1 |
20120123315 | Horvath et al. | May 2012 | A1 |
20120123434 | Grabner et al. | May 2012 | A1 |
20120136306 | Bartha | May 2012 | A1 |
20120165720 | Horvath et al. | Jun 2012 | A1 |
20120191064 | Conston et al. | Jul 2012 | A1 |
20120197175 | Horvath et al. | Aug 2012 | A1 |
20120203160 | Kahook et al. | Aug 2012 | A1 |
20120220917 | Silvestrini et al. | Aug 2012 | A1 |
20120310072 | Grieshaber | Dec 2012 | A1 |
20120310137 | Silvestrini | Dec 2012 | A1 |
20130041346 | Alon | Feb 2013 | A1 |
20130158462 | Wardle et al. | Jun 2013 | A1 |
20130245600 | Yamamoto et al. | Sep 2013 | A1 |
20130253402 | Badawi et al. | Sep 2013 | A1 |
20130274655 | Jennings et al. | Oct 2013 | A1 |
20140066833 | Yaron et al. | Mar 2014 | A1 |
20140081194 | Burns et al. | Mar 2014 | A1 |
20140121584 | Wardle et al. | May 2014 | A1 |
20140128847 | Lopez | May 2014 | A1 |
20140135916 | Clauson et al. | May 2014 | A1 |
20140163448 | Lind et al. | Jun 2014 | A1 |
20140171852 | Khor | Jun 2014 | A1 |
20140194916 | Ichikawa | Jul 2014 | A1 |
20140213958 | Clauson et al. | Jul 2014 | A1 |
20140236066 | Horvath et al. | Aug 2014 | A1 |
20140276332 | Crimaldi et al. | Sep 2014 | A1 |
20140288485 | Berlin | Sep 2014 | A1 |
20140309599 | Schaller | Oct 2014 | A1 |
20140364791 | Stegmann et al. | Dec 2014 | A1 |
20150005623 | Grover et al. | Jan 2015 | A1 |
20150011926 | Reitsamer et al. | Jan 2015 | A1 |
20150051699 | Badawi et al. | Feb 2015 | A1 |
20150065940 | Rangel-Friedman et al. | Mar 2015 | A1 |
20150073328 | Badawi et al. | Mar 2015 | A1 |
20150080783 | Berlin | Mar 2015 | A1 |
20150112372 | Perez Grossmann | Apr 2015 | A1 |
20150119787 | Wardle et al. | Apr 2015 | A1 |
20150125328 | Bourne et al. | May 2015 | A1 |
20150133946 | Horvath et al. | May 2015 | A1 |
20150148615 | Brennan et al. | May 2015 | A1 |
20150216729 | Doci | Aug 2015 | A1 |
20150223981 | Smedley et al. | Aug 2015 | A1 |
20150223983 | Schieber et al. | Aug 2015 | A1 |
20150250649 | Euteneuer et al. | Sep 2015 | A1 |
20150257932 | Pinchuk et al. | Sep 2015 | A1 |
20150282982 | Schieber et al. | Oct 2015 | A1 |
20150313758 | Wilcox | Nov 2015 | A1 |
20150320596 | Gifford, III et al. | Nov 2015 | A1 |
20150335481 | Badawi et al. | Nov 2015 | A1 |
20150374545 | Horvath et al. | Dec 2015 | A1 |
20160022486 | Clauson et al. | Jan 2016 | A1 |
20160051408 | Baerveldt et al. | Feb 2016 | A1 |
20160095985 | Novak | Apr 2016 | A1 |
20160100980 | Badawi et al. | Apr 2016 | A1 |
20160106589 | Mittelstein et al. | Apr 2016 | A1 |
20160135994 | Romoda et al. | May 2016 | A1 |
20160143778 | Aljuri et al. | May 2016 | A1 |
20160151204 | Haffner et al. | Jun 2016 | A1 |
20160220417 | Schieber et al. | Aug 2016 | A1 |
20160220418 | Sorensen et al. | Aug 2016 | A1 |
20160256317 | Horvath et al. | Sep 2016 | A1 |
20160256323 | Horvath et al. | Sep 2016 | A1 |
20160287438 | Badawi et al. | Oct 2016 | A1 |
20160302965 | Erickson et al. | Oct 2016 | A1 |
20160331588 | Ambati et al. | Nov 2016 | A1 |
20160346006 | Hickengbotham et al. | Dec 2016 | A1 |
20160354248 | Kahook | Dec 2016 | A1 |
20170143541 | Badawi et al. | May 2017 | A1 |
20170202707 | Badawi et al. | Jul 2017 | A1 |
20170258507 | Hetherington | Sep 2017 | A1 |
20170348152 | Badawi et al. | Dec 2017 | A1 |
20180271699 | Badawi et al. | Sep 2018 | A1 |
Number | Date | Country |
---|---|---|
2002-541976 | Dec 2002 | JP |
2003-180730 | Jul 2003 | JP |
2005-510317 | Apr 2005 | JP |
2005-538809 | Dec 2005 | JP |
WO-0064393 | Nov 2000 | WO |
WO-03045582 | Jun 2003 | WO |
WO-2004026361 | Apr 2004 | WO |
WO-2005105197 | Nov 2005 | WO |
WO-2005105197 | Nov 2005 | WO |
WO-2005107664 | Nov 2005 | WO |
WO-2005107664 | Nov 2005 | WO |
WO-2005117752 | Dec 2005 | WO |
WO-2006066103 | Jun 2006 | WO |
WO-2006066103 | Jun 2006 | WO |
WO-2008002377 | Jan 2008 | WO |
WO-2009042596 | Apr 2009 | WO |
WO-2009042596 | Apr 2009 | WO |
WO-2011097408 | Aug 2011 | WO |
WO-2011106781 | Sep 2011 | WO |
WO-2013141898 | Sep 2013 | WO |
WO-2016042162 | Mar 2016 | WO |
WO-2016159999 | Oct 2016 | WO |
Entry |
---|
Boyle, E.L. (Feb. 1, 2006). “New Glaucoma Devices Take Different Approaches to IOP Lowering,” Ocular Surgery News U.S. Edition, located at <http://www.osnsupersite.com/view.aspx?rid=12436>, last visited on Apr. 23, 2012, 4 pages, revisited on Apr. 19, 2016, 5 pages. |
Extended European Search Report dated Apr. 22, 2015, for EP Patent Application No. 11 740 372.5, filed Feb. 3, 2011, 6 pages. |
Extended European Search Report dated Jun. 9, 2016, for European Patent Application No. 16 155 079.3, filed on May 31, 2007, 7 pages. |
Extended European Search Report dated May 17, 2011, for European Patent Application No. 11 162 487.0, filed on May 31, 2007, 6 pages. |
Extended European Search Report dated Mar. 24, 2016, for European Patent Application No. 12 871 982.0, filed on Oct. 4, 2012, 7 pages. |
Final Office Action dated Nov. 1, 2010, for U.S. Appl. No. 11/475,523, filed Jun. 26, 2006, 12 pages. |
Final Office Action dated Jul. 19, 2012, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 6 pages. |
Final Office Action dated Feb. 1, 2013, for U.S. Appl. No. 13/020,706, filed Feb. 3, 2011, 6 pages. |
Final Office Action dated Sep. 15, 2014, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 13 pages. |
Final Office Action dated Sep. 20, 2013, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 16 pages. |
Final Office Action dated Nov. 12, 2013, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 8 pages. |
Final Office Action dated Jan. 8, 2014, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 8 pages. |
Final Office Action dated Sep. 3, 2014, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 8 pages. |
Final Office Action dated Apr. 23, 2015, for U.S. Appl. No. 14/527,292, filed Oct. 29, 2014, 8 pages. |
Final Office Action dated Aug. 19, 2015, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 6 pages. |
Final Office Action dated Mar. 9, 2016, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 11 pages. |
Final Office Action dated Oct. 3, 2016, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 27 pages. |
International Search Report dated Nov. 30, 2007, for PCT Application No. PCT/US2007/013038, filed on May 31, 2007, 4 pages. |
International Search Report dated Apr. 5, 2011, for PCT Application No. PCT/US2011/023643, filed on Feb. 3, 2011, 2 pages. |
International Search Report dated Feb. 1, 2013 for PCT Application No. PCT/US2012/058751, filed on Oct. 4, 2012, 4 pages. |
International Search Report dated Sep. 14, 2015, for PCT Application No. PCT/US2015/023720, filed on Mar. 31, 2015, 5 pages. |
Non-Final Office Action dated May 17, 2010, for U.S. Appl. No. 11/475,523, filed Jun. 26, 2006, 10 pages. |
Non-Final Office Action dated Jan. 26, 2012, for U.S. Appl. No. 12/695,053, filed Jan. 27, 2010, 10 pages. |
Non-Final Office Action dated Mar. 15, 2012, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 4 pages. |
Non-Final Office Action dated May 11, 2012, for U.S. Appl. No. 13/020,706, filed Feb. 3, 2011, 5 pages. |
Non-Final Office Action dated Nov. 9, 2012, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 5 pages. |
Non-Final Office Action dated Apr. 24, 2013, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 13 pages. |
Non-Final Office Action dated Jun. 12, 2013, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 8 pages. |
Non-Final Office Action dated Sep. 9, 2013, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 7 pages. |
Non-Final Office Action dated Feb. 7, 2014, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 12 pages. |
Non-Final Office Action dated Feb. 24, 2014, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 12 pages. |
Non-Final Office Action dated May 15, 2014, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 7 pages. |
Non-Final Office Action dated Nov. 28, 2014, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 7 pages. |
Non-Final Office Action dated Jan. 14, 2015, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 10 pages. |
Non-Final Office Action dated Feb. 4, 2015, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 6 pages. |
Non-Final Office Action dated Feb. 23, 2015, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 17 pages. |
Non-Final Office Action dated Jul. 10, 2015, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 16 pages. |
Non-Final Office Action dated Oct. 7, 2015, for U.S. Appl. No. 14/527,292, filed Oct. 29, 2014, 5 pages. |
Non-Final Office Action dated Nov. 3, 2015, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 7 pages. |
Non-Final Office Action dated Dec. 14, 2015, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 7 pages. |
Non-Final Office Action dated Jun. 7, 2016, for U.S. Appl. No. 14/527,292, filed Oct. 29, 2014, 5 pages. |
Non-Final Office Action dated Feb. 25, 2016, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 19 pages. |
Notice of Allowance dated Feb. 2, 2011, for U.S. Appl. No. 11/475,523, filed Jun. 26, 2006, 6 pages. |
Notice of Allowance dated Jun. 11, 2012, for U.S. Appl. No. 12/695,053, filed Jan. 27, 2010, 7 pages. |
Notice of Allowance dated Apr. 2, 2013, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 6 pages. |
Notice of Allowance dated May 10, 2013, for U.S. Appl. No. 13/020,706, filed Feb. 3, 2011, 8 pages. |
Notice of Allowance dated Jul. 7, 2014, for U.S. Appl. No. 14/012,963, filed Aug. 28, 2013, 6 pages. |
Notice of Allowance dated Jul. 23, 2014, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 8 pages. |
Notice of Allowance dated Mar. 30, 2015, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 5 pages. |
Notice of Allowance dated Aug. 10, 2015, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 7 pages. |
Notice of Allowance dated Mar. 1, 2016, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 7 pages. |
Corrected Notice of Allowability dated Apr. 25, 2016, U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 2 pages. |
Notice of Allowance dated Jul. 13, 2016, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 7 pages. |
Corrected Notice of Allowability dated Sep. 1, 2016, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 2 pages. |
Written Opinion dated Nov. 30, 2007, for PCT Application No. PCT/US2007/013038, filed on May 31, 2007, 6 pages. |
Written Opinion dated Apr. 5, 2011, for PCT Application No. PCT/US2011/023643, filed on Feb. 3, 2011, 5 pages. |
Written Opinion dated Feb. 1, 2013 for PCT Application No. PCT/US2012/058751, filed on Oct. 4, 2012, 6 pages. |
Written Opinion dated Sep. 14, 2015 for PCT Application No. PCT/US15/23720, filed on Mar. 31, 2015, 8 pages. |
U.S. Appl. No. 15/343,147, filed Nov. 3, 2016, by Badawi et al. |
U.S. Appl. No. 15/340,911, filed Nov. 1, 2016, by Badawi et al. |
Corrected Notice of Allowability dated Nov. 23, 2018, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 2 pages. |
Final Office Action dated May 18, 2017, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 14 pages. |
Final Office Action dated Jan. 29, 2018, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 19 pages. |
Final Office Action dated Apr. 6, 2018, for U.S. Appl. No. 15/683,652, filed Aug. 22, 2017, 11 pages. |
Final Office Action dated Jun. 1, 2018, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 6 pages. |
Final Office Action dated Oct. 19, 2018, for U.S. Appl. No. 15/683,652, filed Aug. 22, 2017, 8 pages. |
Non-Final Office Action dated Jan. 18, 2017, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 13 pages. |
Non-Final Office Action dated Mar. 22, 2017, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 31 pages. |
Non-Final Office Action dated Aug. 28, 2017, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 6 pages. |
Non-Final Office Action dated Nov. 7, 2017, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 14 pages. |
Non-Final Office Action dated Dec. 15, 2017, for U.S. Appl. No. 15/343,147, filed Nov. 3, 2016, 12 pages. |
Non-Final Office Action dated Apr. 4, 2018, for U.S. Appl. No. 14/675,580, filed Mar. 31, 2015, 10 pages. |
Non-Final Office Action dated Aug. 29, 2018, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 11 pages. |
Non-Final Office Action dated Sep. 20, 2018, for U.S. Appl. No. 15/340,911, filed Nov. 1, 2016, 7 pages. |
Notice of Allowance dated Oct. 25, 2017, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 8 pages. |
Notice of Allowance dated Nov. 21, 2017, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 10 pages. |
Notice of Allowance dated Aug. 31, 2018, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20160287440 A1 | Oct 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11475523 | Jun 2006 | US |
Child | 13025112 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13025112 | Feb 2011 | US |
Child | 15182165 | US |